Novartis has signed a licensing agreement with the Global Alliance for TB Drug Development for compounds against tuberculosis. Novartis will fully transfer its tuberculosis research and development program to the TB Alliance, which will finance and handle ongoing research, development, approval and distribution of the compounds. One of these is NITD304, which blocks a protein associated with the TB bacterium's survival.

Related Summaries